The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.h Nontuberculous pulmonary mycobacterial infection/superinfection

LIX. Infections & related conditions

LIX.m Fungal airway infection

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVII. Mediastinal involvement

XLVII.b Lymphadenopathy with reactive changes

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.a DRES syndrome - DRESS-like reaction

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.f Path: ILD with a granulomatous component (see also Im)

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.av The chemotherapy lung

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.f ARDS and the hemolytic-uremic syndrome (HUS)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.ac Pneumothorax, bilateral

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVII. Mediastinal involvement

XLVII.h Pneumomediastinum

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.f Hiccup

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.o Pneumorachis

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

L. Miscellaneous

L.t Cavitation/necrosis of lung tumor or metastases

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.m Atrial fibrillation

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

LV. Imaging

LV.bh Imaging: Tumoral cavitation

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LV. Imaging

LV.by Imaging: Air or an air crescent around lung tumor or metastase(s)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.g BAL: Atypical epithelial cells (at times poetically named

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LVIII. Pathology

LVIII.ba Path: Thrombosis in pulmonary arterioles/venules

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.bx Path: Granulomatous lymphadenopathy

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

LIX. Infections & related conditions

LIX.r Fungal infection (pulmonary/extrapulmonary)

LIX. Infections & related conditions

LIX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

LX. Neoplastic conditions

LX.d Malignant mesothelioma (pleural, pericardial)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

LVIII. Pathology

LVIII.k Path: Desquamative interstitial pneumonia (DIP-pattern)

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

LIX. Infections & related conditions

LIX.q Viral pneumonia

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLVII. Mediastinal involvement

XLVII.b Lymphadenopathy with reactive changes

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.aa Subclinical ANA positivity

L. Miscellaneous

L.c Pleuritic chest pain

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.g BAL: Atypical epithelial cells (at times poetically named

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

LVIII. Pathology

LVIII.cl Path: Post-transplant lymphoproliferative disease (PTLD)

LIX. Infections & related conditions

LIX.l Scedosporium pulmonary infection

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)